Advertisement
Screener

Anika Therapeutics, Inc. (ANIK) Overview

Anika Therapeutics, Inc. (ANIK) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.24; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.37; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.16; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.28; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$8.67$10.55$12.84$15.62$19.01$23.132025-11-062026-11-06$7.70$10.90$15.43$21.84$30.92$43.792021-11-082026-11-06$7.70$12.20$19.34$30.65$48.59$77.032016-11-072026-11-06$2.85$5.51$10.66$20.60$39.84$77.032006-11-062026-11-06$0.71$1.82$4.64$11.83$30.19$77.031993-05-032026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$14.54
Previous close
$19.95
Change
-$5.42
Change (%)
-27.14%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ANIK
+107.60%
S&P 500
(m)

1 year

ANIK
+118.27%
S&P 500
(m)

3 years

ANIK
+7.09%
S&P 500
(m)

5 years

ANIK
-51.75%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.24

-0.45-0.23-0.020.200.4231 Mar 2025: estimate (m); actual -0.3431 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.2830 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.1630 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.3731 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.2430 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.24(m)(m)
1 Jan 202631 Mar 2026(m)-0.37(m)(m)
1 Jul 202530 Sept 2025(m)-0.16(m)(m)
1 Apr 202530 Jun 2025(m)-0.28(m)(m)
1 Jan 202531 Mar 2025(m)-0.34(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.76

-5.72-4.17-2.63-1.080.4631 Dec 2021: estimate (m); actual 0.2831 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.0231 Dec 2022(m)31 Dec 2023: estimate (m); actual -5.6431 Dec 2023(m)31 Dec 2024: estimate (m); actual -3.8331 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.7631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.76(m)(m)
1 Jan 202431 Dec 2024(m)-3.83(m)(m)
1 Jan 202331 Dec 2023(m)-5.64(m)(m)
1 Jan 202231 Dec 2022(m)-1.02(m)(m)
1 Jan 202131 Dec 2021(m)0.28(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 32.61M ■ Earnings 3.31M — Profit margin 10.15%

-9.58M-18.1%5.99M-8.3%21.56M1.4%37.13M11.1%30 Sept 2025: revenue 27.82M; earnings -2.33M; profit margin -8.37%30 Sept 202531 Dec 2025: revenue 30.61M*; earnings 0.17M*; profit margin 0.56%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 29.61M; earnings -5.06M; profit margin -17.07%31 Mar 202630 Jun 2026: revenue 32.61M; earnings 3.31M; profit margin 10.15%30 Jun 2026

31 Dec 2025 ■ Revenue 112.82M ■ Earnings -11.00M — Profit margin -9.75%

-107.46M-69.7%-23.22M-49.4%61.01M-29.1%145.25M-8.8%31 Dec 2022: revenue 113.83M; earnings -15.00M; profit margin -13.18%31 Dec 202231 Dec 2023: revenue 120.79M; earnings -83.00M; profit margin -68.71%31 Dec 202331 Dec 2024: revenue 119.91M; earnings -56.00M; profit margin -46.70%31 Dec 202431 Dec 2025: revenue 112.82M; earnings -11.00M; profit margin -9.75%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$14.54(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$14.54High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning ANIK

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Index membership
(m)
Employees
235.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
78.23K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-4.50%*
Total return · month
-5.45%*
Total return · quarter
32.91%*
Total return · half year
39.71%*
Total return · year to date
107.60%*
Total return · 1 year
118.27%*
Total return · 3 years
7.09%*
Total return · 5 years
-51.75%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Anika Therapeutics, Inc. Overview

View more →

(m)

(m)

SEC CIK
898437
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Country of operation
United States
Business address
32 WIGGINS AVENUE, BEDFORD, Massachusetts, 01730, United States
Fiscal year end
1231
Phone
(781) 457-9000

Similar stocks

Stock NameCountryMarket CapPE Ratio
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
Cytosorbents Corp (CTSO)United States$0.274B-1.29
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
InfuSystem Holdings, Inc (INFU)United States$0.253B22.52
Mobia Medical, Inc. (MOBI)United States$0.293B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
PRO DEX INC (PDEX)United States$0.234B13.64
Embecta Corp. (EMBC)United States$0.319B2.10
Neuronetics, Inc. (STIM)United States$0.216B-3.25